X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs TORRENT PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA TORRENT PHARMA SUN PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 29.1 60.0 48.5% View Chart
P/BV x 2.4 5.7 43.0% View Chart
Dividend Yield % 0.5 0.9 57.3%  

Financials

 SUN PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
TORRENT PHARMA
Mar-18
SUN PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs7011,550 45.2%   
Low Rs4331,144 37.9%   
Sales per share (Unadj.) Rs110.4354.7 31.1%  
Earnings per share (Unadj.) Rs11.040.1 27.4%  
Cash flow per share (Unadj.) Rs17.264.2 26.8%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.41.0 33.9%  
Book value per share (Unadj.) Rs158.8273.1 58.1%  
Shares outstanding (eoy) m2,399.26169.22 1,417.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.8 135.2%   
Avg P/E ratio x51.633.6 153.7%  
P/CF ratio (eoy) x32.921.0 156.9%  
Price / Book Value ratio x3.64.9 72.4%  
Dividend payout %18.234.9 52.2%   
Avg Mkt Cap Rs m1,360,021227,897 596.8%   
No. of employees `00017.814.7 121.0%   
Total wages/salary Rs m53,67111,353 472.8%   
Avg. sales/employee Rs Th14,890.94,083.0 364.7%   
Avg. wages/employee Rs Th3,017.1772.3 390.7%   
Avg. net profit/employee Rs Th1,480.6461.3 320.9%   
INCOME DATA
Net Sales Rs m264,89560,021 441.3%  
Other income Rs m8,3882,988 280.7%   
Total revenues Rs m273,28263,009 433.7%   
Gross profit Rs m56,08113,493 415.6%  
Depreciation Rs m14,9984,086 367.1%   
Interest Rs m5,1763,085 167.8%   
Profit before tax Rs m44,2959,310 475.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4522,529 334.2%   
Profit after tax Rs m26,3386,781 388.4%  
Gross profit margin %21.222.5 94.2%  
Effective tax rate %19.127.2 70.3%   
Net profit margin %9.911.3 88.0%  
BALANCE SHEET DATA
Current assets Rs m316,35952,623 601.2%   
Current liabilities Rs m198,64352,022 381.8%   
Net working cap to sales %44.41.0 4,434.3%  
Current ratio x1.61.0 157.4%  
Inventory Days Days95120 79.3%  
Debtors Days Days10876 141.3%  
Net fixed assets Rs m213,17885,016 250.7%   
Share capital Rs m2,399846 283.5%   
"Free" reserves Rs m378,60645,376 834.4%   
Net worth Rs m381,00646,222 824.3%   
Long term debt Rs m17,72141,115 43.1%   
Total assets Rs m643,028142,432 451.5%  
Interest coverage x9.64.0 237.9%   
Debt to equity ratio x00.9 5.2%  
Sales to assets ratio x0.40.4 97.8%   
Return on assets %4.96.9 70.7%  
Return on equity %6.914.7 47.1%  
Return on capital %10.014.2 70.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81614,580 279.9%   
Fx outflow Rs m30,1433,600 837.3%   
Net fx Rs m10,67310,980 97.2%   
CASH FLOW
From Operations Rs m39,0728,942 437.0%  
From Investments Rs m-33,708-47,070 71.6%  
From Financial Activity Rs m-15,39334,174 -45.0%  
Net Cashflow Rs m-7,359-3,655 201.3%  

Share Holding

Indian Promoters % 63.7 71.5 89.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 7.0 73.1%  
FIIs % 23.0 12.6 182.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 8.8 94.3%  
Shareholders   133,026 26,511 501.8%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  STERLING BIOTECH  CADILA HEALTHCARE  ALEMBIC LTD  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Over 300 Points Higher; Energy and Metal Stocks Witness Buying(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)

Jun 20, 2019

The next big opportunity that has the potential to make you both rich and healthy.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 25, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS